Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland. Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2 inhibitor, approved in the United States for the treatment of patients with polycythemia vera ('PV'),who have had an inadequate response to or are intolerant to hydroxyurea. It is also approved for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-PV MF, and post-essential thrombocythemia MF. The drug is also approved in the United States for treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients aged 12 years or older.
| Revenue (Most Recent Fiscal Year) | $3.70B |
| Net Income (Most Recent Fiscal Year) | $597.60M |
| PE Ratio (Current Year Earnings Estimate) | 13.39 |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | 0.50 |
| Price to Sales Ratio (Trailing 12 Months) | 3.29 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.22 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 28.56 |
| Pre-Tax Margin (Trailing 12 Months) | 6.72% |
| Net Margin (Trailing 12 Months) | 0.80% |
| Return on Equity (Trailing 12 Months) | -0.63% |
| Return on Assets (Trailing 12 Months) | -0.45% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.87 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.82 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.01 |
| Inventory Turnover (Trailing 12 Months) | 2.32 |
| Book Value per Share (Most Recent Fiscal Quarter) | $23.16 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.73 |
| Earnings per Share (Most Recent Fiscal Year) | $2.69 |
| Diluted Earnings per Share (Trailing 12 Months) | $0.14 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 192.65M |
| Free Float | 158.74M |
| Market Capitalization | $13.39B |
| Average Volume (Last 20 Days) | 1.61M |
| Beta (Past 60 Months) | 0.71 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 17.60% |
| Percentage Held By Institutions (Latest 13F Reports) | 96.97% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |